overactive bladder

Sacral neuromodulation, botulinum show equal efficacyIn patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial.
Foot stimulation may offer home-based OAB treatmentNew research may pave the way for a form of nerve stimulation for refractory overactive bladder that is home based and less invasive than current neuromodulation approaches.
Small Doses: Pharmacy News Featuring Opioids, Ketamine, and More
Small Doses: Pharmacy News Featuring Opioids, Ketamine, and MoreSmall Doses is news for pharmacists in a way that works for you.
New Products: Neuromodulation system for OAB targets tibial nerveOther products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Brain activity in OAB patients characterized in studyPreliminary findings of a Swiss study revealed that the brain activity associated with the desire to void in response to the automated, repetitive filling and distention of the bladder with body warm saline differed greatly between healthy patients and patients with non-neurogenic overactive bladder.
Botulinum formulations show slight outcomes differencesA new comparative study showed that the use of intradetrusor injections of abobotulinum toxin A (Dysport) for urinary incontinence due to neurogenic detrusor overactivity provided results that were similar to or superior to those seen with onabotulinum toxin A (Botox), depending on the dosage of the latter.
Treatment of OAB may reduce fall risk in older patientsOveractive bladder (OAB) and falls often carry a substantial burden for patients and society as a whole, and new research suggests that treatment of OAB may lower fall risk. Learn more
PTNS efficacy bolstered by adjunctive pharmacotherapyStudy examines real-world effectiveness of percutaneous tibial nerve stimulation for treating overactive bladder.
CNS may be path to future voiding dysfunction therapiesIn this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCaOther pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.